Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed, incurable solid tumor that is
unresectable or has distant metastasis for which a more effective therapy does not exist
No active CNS metastasis

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
least 8 weeks Hematopoietic: WBC at least 3000/mm3 Absolute neutrophil count at least
1500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL
Transaminases no greater than 2.5 times normal PT and PTT no greater than 1.25 times upper
limit of normal Renal: Creatinine no greater than 1.4 mg/dL Creatinine clearance at least
60 mL/min Cardiovascular: No myocardial infarction within past 6 months No congestive
heart failure or serious arrhythmias requiring treatment Other: No greater than grade 2
neuropathy (including hearing loss) No frequent vomiting or severe anorexia No recent loss
of greater than 10% of body weight Not pregnant or nursing Fertile patients must use
effective birth control during and for at least 6 months after study No serious concurrent
medical illness that would preclude study

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy and
recovered from toxic effects No concurrent immunotherapy Chemotherapy: At least 4 weeks
since prior chemotherapy (at least 6 weeks since prior mitomycin or nitrosoureas) and
recovered No other concurrent chemotherapy Endocrine therapy: Concurrent hormonal therapy
allowed if patient has progressive disease while receiving hormonal therapy for at least
three months Radiotherapy: At least 4 weeks since prior radiotherapy and recovered No
concurrent radiation therapy Surgery: At least 21 days since prior major surgery Other:
Any drugs that affect hepatic or renal function must be given as a stable dose and should
not be initiated after patient enters study